COVID-19 vaccine candidate in China.The randomized, placebo-controlled, observer-blinded Phase 1 clinical trial in China will enroll 144 healthy subjects to evaluate the safety and immunogenicity of the vaccine as well as to confirm dose selection, BioNTech said in a statement."The study is designed to support the regulatory approval process for the Chinese market and intends to confirm that the safety and immunogenicity profile observed in participants from the German and U.S.
trials is comparable to that of Chinese participants," BioNTech said in a statement.The trial is part of BioNTech’s global development program aimed at supporting a global supply upon regulatory approval.BioNTech said the dose range selection was determined based on.